(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous… Read on
(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat… Read on
(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers… Read on
(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment… Read on
(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage… Read on
(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery… Read on
(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer… Read on
(November 13, 2018) The International Journal of Cancer recently published a study that explored the use of statins, which reduces one’s lipids, and their effect on ovarian cancer risk… Read on
(October 25, 2018) Through a series of surveys, interviews, and literature reviews the World Ovarian Cancer Coalition produced a report that detailed their findings and recommendations… Read on
(October 23, 2018) Olaparib, or Lynparza, was shown to increase progression-free survival (PFS) by almost three years in an ongoing trial known as SOLO-1… Read on
